Form 6-K VectivBio Holding AG For: Dec 09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of December 2022
Commission File Number 001-40316
VECTIVBIO HOLDING AG
(Exact name of registrant as specified in its charter)
Aeschenvorstadt 36
4051 Basel
Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Announcement of Results of the Companys Extraordinary General Meeting of Shareholders
On December 9, 2022, VectivBio Holding AG, or the Company, issued a press release announcing the results of the Companys Extraordinary General Meeting of Shareholders, which was held at 10:00 a.m. (Swiss time) on December 9, 2022, at the Companys offices at Aeschenvorstadt 36, 4051 Basel, Switzerland. A copy of the press release is filed as Exhibit 99.1 hereto.
Incorporation by Reference
The Company hereby incorporates by reference the information contained in the body of this Report on Form 6-K and in Exhibit 99.1 into the Companys registration statements on Form S-8 (File No. 333-255524) and Form F-3 (File Nos. 333-264653 and 333-265546) (including any prospectuses forming a part of such registration statements) and deems them to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibits |
||
99.1 | Press Release, dated December 9, 2022. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VECTIVBIO HOLDING AG | ||||||
December 9, 2022 | By: | /s/ Luca Santarelli | ||||
Luca Santarelli | ||||||
Chief Executive Officer |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VAALCO Schedules First Quarter 2024 Earnings Release and Conference Call
- ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
- AGM Trading Update - April 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!